Compare two induction treatments for newly diagnosed high-risk AML
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether one initial chemotherapy approach works better than another in people newly diagnosed with high-risk acute myeloid leukemia (AML). You may benefit if your disease is high-risk, and the study will also compare how well the treatments control the leukemia and how safely they work.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 64 years old, and you can participate regardless of sex.
- You have newly diagnosed AML (not a later-stage or relapsed AML), based on a 2022 classification standard.
- Your AML has “adverse/high-risk” features based on a 2022 risk system.
- You have not had AML treatment yet, except limited short-term medicines like hydroxyurea or very low-dose cytarabine with a small total dose.
- Your body function tests are adequate: you can meet liver limits (bilirubin and AST/ALT within ranges) and kidney limits (creatinine clearance ≥ 30).
- You can do daily activities with only limited limits (ECOG 0 to 2) and you can sign consent to understand the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This study tests a combination of two drugs (MDCyta and venetoclax) after an initial treatment to see if it helps people with newly diagnosed AML stay in remission. It is for adults aged 18 to 60 who are otherwise fairly healthy.
This early-phase study tests whether venetoclax combined with intensive chemotherapy can treat AML (acute leukemia) and certain advanced MDS. It’s for people who are newly diagnosed (or certain high-risk blood cancers) and can safely tolerate strong treatment.
This trial tests a combination of three drugs—daunorubicin, cytarabine, and venetoclax—for people with newly diagnosed AML who are strong enough to receive intensive chemotherapy. The goal is to see if adding venetoclax helps improve treatment outcomes.
This Phase 2 trial compares two treatment approaches for people newly diagnosed with a specific type of AML (bone marrow cancer) that has an NPM1 mutation: venetoclax plus azacitidine versus intensive (strong) chemotherapy. It aims to see which plan works better and is safer for “fit” patients.
This trial tests a combination of two chemotherapy drugs (idarubicin and cytarabine) at lower doses plus a targeted drug called venetoclax for adults newly diagnosed with acute myeloid leukemia or high-risk myelodysplastic syndrome. The goal is to see if this reduced-intensity treatment is effective with fewer side effects.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.